See more : SilverBow Resources, Inc. (SBOW) Income Statement Analysis – Financial Results
Complete financial analysis of CG Oncology, Inc. Common stock (CGON) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CG Oncology, Inc. Common stock, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Pharmicell Co., Ltd. (005690.KS) Income Statement Analysis – Financial Results
- Kanoria Chemicals & Industries Limited (KANORICHEM.NS) Income Statement Analysis – Financial Results
- APCB Inc. (6108.TW) Income Statement Analysis – Financial Results
- Premier Investments Limited (PMV.AX) Income Statement Analysis – Financial Results
- NameSilo Technologies Corp. (URLOF) Income Statement Analysis – Financial Results
CG Oncology, Inc. Common stock (CGON)
Industry: Biotechnology
Sector: Healthcare
About CG Oncology, Inc. Common stock
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 204.00K | 191.00K | 10.36M |
| Cost of Revenue | 0.00 | 15.00K | 10.00K |
| Gross Profit | 204.00K | 176.00K | 10.35M |
| Gross Profit Ratio | 100.00% | 92.15% | 99.90% |
| Research & Development | 45.75M | 29.03M | 18.32M |
| General & Administrative | 9.90M | 6.41M | 4.65M |
| Selling & Marketing | 0.00 | -15.00K | -10.00K |
| SG&A | 9.90M | 6.39M | 4.64M |
| Other Expenses | 0.00 | -196.00K | 218.00K |
| Operating Expenses | 55.65M | 35.42M | 22.95M |
| Cost & Expenses | 55.65M | 35.44M | 22.96M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 1.00K | 451.00K |
| Depreciation & Amortization | 17.00K | 15.00K | 10.00K |
| EBITDA | -55.43M | -35.23M | -12.38M |
| EBITDA Ratio | -27,172.55% | -18,445.55% | -121.61% |
| Operating Income | -55.45M | -35.25M | -12.61M |
| Operating Income Ratio | -27,180.88% | -18,453.40% | -121.70% |
| Total Other Income/Expenses | 6.84M | -197.00K | -233.00K |
| Income Before Tax | -48.61M | -35.44M | -12.84M |
| Income Before Tax Ratio | -23,826.96% | -18,556.54% | -123.95% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 |
| Net Income | -48.61M | -35.44M | -12.84M |
| Net Income Ratio | -23,826.96% | -18,556.54% | -123.95% |
| EPS | -15.65 | -0.53 | -0.19 |
| EPS Diluted | -15.65 | -0.53 | -0.19 |
| Weighted Avg Shares Out | 4.33M | 66.64M | 66.64M |
| Weighted Avg Shares Out (Dil) | 4.33M | 66.64M | 66.64M |
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
SCHAUMBURG, Ill. and IRVINE, Calif.
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical companies.
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman &...
CG Oncology: Promising Data, But Looks Expensive
CG Oncology's bladder cancer molecule, cretostimogene, showed high success with a 75.2% complete response rate in a phase 3 monotherapy study. Cretostimogene, an oncolytic immunotherapy, works by selectively replicating in cancer cells and encoding GM-CSF to activate the immune system....
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
– Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature Medicine and featured at ASCO 2024 – – Announced 54% complete response (CR) rate in the intention-to-treat...
CG Oncology Bringing Undervalued Innovation To Bladder Cancer
CG Oncology's cretostimogene shows high potential to disrupt the NMIBC market with promising efficacy and safety data. The company is initially targeting high-risk NMIBC patients who no longer respond to the BCG vaccine, but intermediate-risk patients could bring the addressable...
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
IRVINE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced final results from the Phase...
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response (CR) Rate at Any Time in Bacillus Calmette Guerin (BCG)-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-Risk NMIBC (IR-NMIBC) Final Results from...
Source: https://incomestatements.info
Category: Stock Reports